{ }
Symbol RAPT
Name RAPT Therapeutics, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State CA
City South San Francisco
Zipcode 94080
Website http://www.rapt.com
Rapt Therapeutics has pivoted after halting its lead program, agreeing to pay $35 million for RPT904, a long-acting anti-IgE antibody in development by Shanghai Jemincare. Targeting food allergies, Rapt aims to start a phase 2b trial next year, anticipating peak U.S. sales of $4.5 billion. Investors have backed the biotech with $150 million, extending its cash runway through the expected delivery of trial data in 2027.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.